Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Capital Expenditures (2016 - 2024)

Biomerica's Capital Expenditures history spans 15 years, with the latest figure at $24000.0 for Q2 2024.

  • For Q2 2024, Capital Expenditures changed N/A year-over-year to $24000.0; the TTM value through May 2024 reached $51000.0, down 20.31%, while the annual FY2024 figure was $51000.0, 20.31% down from the prior year.
  • Capital Expenditures for Q2 2024 was $24000.0 at Biomerica, up from $6000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $45194.0 in Q1 2021 and bottomed at $5141.0 in Q3 2021.
  • The 5-year median for Capital Expenditures is $21689.5 (2020), against an average of $20946.3.
  • The largest annual shift saw Capital Expenditures skyrocketed 1723.49% in 2020 before it crashed 87.01% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $21978.0 in 2020, then tumbled by 40.53% to $13071.0 in 2021, then skyrocketed by 83.61% to $24000.0 in 2022, then crashed by 75.0% to $6000.0 in 2023, then soared by 300.0% to $24000.0 in 2024.
  • Per Business Quant, the three most recent readings for BMRA's Capital Expenditures are $24000.0 (Q2 2024), $6000.0 (Q4 2023), and $21000.0 (Q3 2023).